A Study in Parkinson's Disease in Patients With Moderate to Severe Dyskinesia

Summary

The current study will explore the efficacy, safety and tolerability of 2 dose combinations of JM-010 to determine the optimal doses of each component to be studied in confirmatory clinical trials.

Timeline

Start

2019-07-22

Primary completion

2024-03-07

Completion

2024-03-21

Outcome

Missed primary endpoint

release “Unfortunately, the primary endpoint assessing reduction in dyskinesia as evaluated by the UDysRS was not met. The ASTORIA trial was well conducted” conterapharma.com ↗

Publications

• McFarthing K, Prakash N, Simuni T. CLINICAL TRIAL HIGHLIGHTS - DYSKINESIA. J Parkinsons Dis. 2019;9(3):449-465. doi: 10.3233/JPD-199002. No abstract available.

Drugs

Indications